Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Pooja, Kulkarni"'
Publikováno v:
Preventive Medicine Reports, Vol 36, Iss , Pp 102514- (2023)
Introduction: The Medicare annual wellness visit was designed to address health risks and encourage evidence-based preventive care in aging. However, it can be challenging for providers to dedicate time for comprehensive attention to wellness during
Externí odkaz:
https://doaj.org/article/d825922666104454841ba3685ea443b6
Autor:
Pooja Kulkarni, Deepika Beeraka, Meghana Tanwar, Usha Kim, Rajniganth Mahalingam Ganesan, Pragya Saini
Publikováno v:
Indian Journal of Ophthalmology, Vol 71, Iss 7, Pp 2906-2910 (2023)
Rhino-orbito-cerebral mucormycosis (ROCM) is the most commonly noted form of mucormycosis, which is the most common secondary fungal infection following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Osteomyelitis is one of t
Externí odkaz:
https://doaj.org/article/cf1e0730f3ac4cc5a76e57acb7bffb34
Autor:
Munjal Patel, Francesco Bellanti, Naveen M. Daryani, Nadia Noormohamed, David W. Hilbert, Katherine Young, Pooja Kulkarni, William Copalu, Ferdous Gheyas, Matthew L. Rizk
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 2, Pp 396-408 (2022)
Abstract In the phase III RESTORE‐IMI 2 study (ClinicalTrials.gov: NCT02493764), the combination antibacterial agent imipenem/cilastatin/relebactam (IMI/REL) demonstrated noninferiority to piperacillin/tazobactam for the end points of all‐cause m
Externí odkaz:
https://doaj.org/article/2fe004e1c4e6439c87c133441ff0e7a8
Autor:
Pratik Bhagunde, Parul Patel, Mallika Lala, Kenny Watson, William Copalu, Ming Xu, Pooja Kulkarni, Katherine Young, Matthew L. Rizk
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 10, Pp 748-758 (2019)
Relebactam is a small‐molecule β‐lactamase inhibitor developed as a fixed‐dose combination with imipenem/cilastatin. The pharmacokinetics of relebactam and imipenem across 10 clinical studies were analyzed using data from adult healthy volunte
Externí odkaz:
https://doaj.org/article/16930bafa9fd42f6b4ceaac5cf976f1b
Publikováno v:
Indian Journal of Ophthalmology, Vol 70, Iss 6, Pp 2169-2169 (2022)
Externí odkaz:
https://doaj.org/article/50a00047801b49c7be49cb8a9bcf9459
Autor:
Alok Sharma, Hemangi Sane, Nandini Gokulchandran, Suhasini Pai, Pooja Kulkarni, Vaishali Ganwir, Maitree Maheshwari, Ridhima Sharma, Meenakshi Raichur, Samson Nivins, Prerna Badhe
Publikováno v:
Stem Cell Research & Therapy, Vol 9, Iss 1, Pp 1-14 (2018)
Abstract Background The underlying pathophysiology in intellectual disability (ID) involves abnormalities in dendritic branching and connectivity of the neuronal network. This limits the ability of the brain to process information. Conceptually, cell
Externí odkaz:
https://doaj.org/article/fae343b4100047bc860ad45619e5ed7e
Publikováno v:
Orbit. :1-4
A 7-year-old girl presented with a painless firm to cystic mass in the infero-temporal quadrant of her right orbit since birth. The mass had recurred with a cutaneous sinus after initial surgery. Right eye vision was affected by mass induced astigmat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a26724a2ceb29b1f07c60f3e47e05f7
https://doi.org/10.1080/01676830.2022.2072900
https://doi.org/10.1080/01676830.2022.2072900
Publikováno v:
ECS Transactions. 107:18091-18105
CSR is moral responsibility and obligation of corporate world to contribute towards social cause and sustainable development of the community at large. Purpose of study was to find, compare, and analyze the extent of CSR activities undertaken and fun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b76a8cfb3fa70ebc46bebc761a51aa56
https://doi.org/10.1149/10701.18091ecst
https://doi.org/10.1149/10701.18091ecst
Publikováno v:
Orbit. :1-5
Epidermal nevus syndrome is a rare congenital disorder affecting only a few hundred people in the world. It has ophthalmic, dermatological, and neurological manifestations, with varied presentation. Here, we report a case of two-year-old child who pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ecbd8e383a1f4dfca228a1dde4b0c21
https://doi.org/10.1080/01676830.2022.2049609
https://doi.org/10.1080/01676830.2022.2049609
Autor:
Katherine Young, Ferdous Gheyas, Francesco Bellanti, Pooja Kulkarni, David W. Hilbert, Munjal Patel, William Copalu, Matthew L. Rizk, Naveen M. Daryani, Nadia Z. Noormohamed
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 2, Pp 396-408 (2022)
In the phase III RESTORE‐IMI 2 study (ClinicalTrials.gov: NCT02493764), the combination antibacterial agent imipenem/cilastatin/relebactam (IMI/REL) demonstrated noninferiority to piperacillin/tazobactam for the end points of all‐cause mortality
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::568dd7388abaccc3b763d679304fd2a7
https://doi.org/10.1111/cts.13158
https://doi.org/10.1111/cts.13158